Multi Institutional Study in Patient Presenting With Hematuria
NCT03122964 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1148
Last updated 2019-03-06
Summary
The primary objective of this study is to evaluate the performance of the methylation marker panel for the detection of bladder cancer in patients with gross or microscopic hematuria.
Conditions
- Bladder Cancer
- Hematuria
Interventions
- DIAGNOSTIC_TEST
-
AssureMDx
combined panel of methylation and mutation markers for the detection of bladder cancer
Sponsors & Collaborators
-
MDx Health
lead INDUSTRY
Eligibility
- Min Age
- 40 Years
- Max Age
- 85 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2017-03-31
- Primary Completion
- 2020-02-28
- Completion
- 2020-02-28
Countries
- United States
Study Locations
More Related Trials
-
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
NCT05366881 ·Status: RECRUITING
-
Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer
NCT00095589 ·Status: COMPLETED
-
Clinical Study of Pan-cancer DNA Methylation Test in Plasma
NCT05685524 ·Status: UNKNOWN
-
Genetic Susceptibility to Bladder Cancer
NCT00848289 ·Status: ACTIVE_NOT_RECRUITING
-
ctDNA in Subjects With Muscle-invasive Bladder Cancer Treated With Trimodality Therapy
NCT05630131 ·Status: COMPLETED
-
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
NCT00026884 ·Status: RECRUITING
-
Metadherin mRNA Expression in Bladder Cancer
NCT04286672 ·Status: UNKNOWN
-
Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study
NCT06339138 ·Status: ACTIVE_NOT_RECRUITING
-
Real-time Monitoring of Concentration and Size Variations of Circulating Plasma Free DNA to Predict Early Response to Immunotherapies in Patients With Different Types of Cancer.
NCT05083494 ·Status: UNKNOWN
-
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069 ·Status: RECRUITING
-
Disease Burden and Biology Using Tumor Cell Free DNA in Metastatic Kidney Cancer
NCT04883827 ·Status: COMPLETED
-
Cancer DNA Detection in Blood and Urine
NCT02657863 ·Status: COMPLETED
-
Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer
NCT00582387 ·Status: COMPLETED
-
Urine Proteome of Surgical Patients and Healthy Volunteers
NCT01538823 ·Status: COMPLETED
-
Cell-free DNA in Hereditary And High-Risk Malignancies 1
NCT04261972 ·Status: ACTIVE_NOT_RECRUITING
-
Biomarker Identification for Bladder Cancer Patients
NCT02053662 ·Status: TERMINATED
-
Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)
NCT05917106 ·Status: RECRUITING
-
A Genotype-Phenotype Urothelial Cancer Registry
NCT00902590 ·Status: ACTIVE_NOT_RECRUITING
-
Cell-free DNA Methylation Markers for Cancer Screening
NCT03096938 ·Status: UNKNOWN ·Phase: NA
-
Detection Evaluation of a Novel Blood-based DNA Methylation Assay in Early-stage Hepatocellular Carcinoma Patients
NCT05343832 ·Status: UNKNOWN
-
Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer
NCT02664883 ·Status: ACTIVE_NOT_RECRUITING
-
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
NCT05181826 ·Status: RECRUITING
-
A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer
NCT03617939 ·Status: RECRUITING
-
Urothelial Cancer Screening in Individuals With Lynch Syndrome Using a Urine Tumor DNA Panel (LS-URO Study)
NCT06218433 ·Status: RECRUITING ·Phase: NA
-
Exploration of DNA Methylation as a Marker for Early Detection of High Grade Serous Epithelial Ovarian Cancer
NCT03622385 ·Status: COMPLETED